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Overview {#bph13352-sec-0003}
========

Nuclear hormone receptors are specialised transcription factors with commonalities of sequence and structure, which bind as homo‐ or heterodimers to specific consensus sequences of DNA (response elements) in the promoter region of particular target genes. They regulate (either promoting or repressing) transcription of these target genes in response to a variety of endogenous ligands. Endogenous agonists are hydrophobic entities which, when bound to the receptor promote conformational changes in the receptor to allow recruitment (or dissociation) of protein partners, generating a large multiprotein complex.

Two major subclasses of nuclear receptors with identified endogenous agonists can be identified: steroid and non‐steroid hormone receptors. Steroid hormone receptors function typically as dimeric entities and are thought to be resident outside the nucleus in the unliganded state in a complex with chaperone proteins, which are liberated upon agonist binding. Migration to the nucleus and interaction with other regulators of gene transcription, including RNA polymerase, acetyltransferases and deacetylases, allows gene transcription to be regulated. Non‐steroid hormone receptors typically exhibit a greater distribution in the nucleus in the unliganded state and interact with other nuclear receptors to form heterodimers, as well as with other regulators of gene transcription, leading to changes in gene transcription upon agonist binding.

Selectivity of gene regulation is brought about through interaction of nuclear receptors with particular consensus sequences of DNA, which are arranged typically as repeats or inverted palindromes to allow accumulation of multiple transcription factors in the promoter regions of genes.

Family structure {#bph13352-sec-0004}
================

[5958 1A. Thyroid hormone receptors](#bph13352-sec-0005){ref-type="sec"}

[5959 1B. Retinoic acid receptors](#bph13352-sec-0009){ref-type="sec"}

[5960 1C. Peroxisome proliferator‐activated receptors](#bph13352-sec-0013){ref-type="sec"}

[5961 1D. Rev‐Erb receptors](#bph13352-sec-0017){ref-type="sec"}

[5962 1F. Retinoic acid‐related orphans](#bph13352-sec-0020){ref-type="sec"}

[5963 1H. Liver X receptor‐like receptors](#bph13352-sec-0024){ref-type="sec"}

[5964 1I. Vitamin D receptor‐like receptors](#bph13352-sec-0028){ref-type="sec"}

[5965 2A. Hepatocyte nuclear factor‐4 receptors](#bph13352-sec-0031){ref-type="sec"}

[5966 2B. Retinoid X receptors](#bph13352-sec-0034){ref-type="sec"}

[5967 2C. Testicular receptors](#bph13352-sec-0037){ref-type="sec"}

[5968 2E. Tailless‐like receptors](#bph13352-sec-0040){ref-type="sec"}

[5969 2F. COUP‐TF‐like receptors](#bph13352-sec-0043){ref-type="sec"}

[5970 3B. Estrogen‐related receptors](#bph13352-sec-0046){ref-type="sec"}

[5971 4A. Nerve growth factor IB‐like receptors](#bph13352-sec-0049){ref-type="sec"}

[5972 5A. Fushi tarazu F1‐like receptors](#bph13352-sec-0052){ref-type="sec"}

[5973 6A. Germ cell nuclear factor receptors](#bph13352-sec-0055){ref-type="sec"}

[5974 0B. DAX‐like receptors](#bph13352-sec-0058){ref-type="sec"}

[5975 Steroid hormone receptors](#bph13352-sec-0061){ref-type="sec"}

[5975 3A. Estrogen receptors](#bph13352-sec-0063){ref-type="sec"}

[5976 3C. 3‐Ketosteroid receptors](#bph13352-sec-0066){ref-type="sec"}

[1A. Thyroid hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=84) {#bph13352-sec-0005}
=========================================================================================================

Overview {#bph13352-sec-0006}
--------

Thyroid hormone receptors (**TRs, nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**41**](http://www.ncbi.nlm.nih.gov/pubmed/17132849?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR1A family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine ([T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635)) and thyroid hormone ([triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634)). Once activated by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family. [NH‐3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2633) has been described as an antagonist at TRs with modest selectivity for TRβ\[[111](http://www.ncbi.nlm.nih.gov/pubmed/12109914?dopt=AbstractPlus)\]. Nomenclature[Thyroid hormone receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=588)[Thyroid hormone receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=589)Systematic nomenclatureNR1A1NR1A2HGNC, UniProt[THRA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11796), [P10827](http://www.uniprot.org/uniprot/P10827)[THRB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11799), [P10828](http://www.uniprot.org/uniprot/P10828)Rank order of potency[triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634)\>[T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635)[triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634)\>[T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635)Agonists[dextrothyroxine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6951) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/6777394?dopt=AbstractPlus)\][dextrothyroxine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6951) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/6777394?dopt=AbstractPlus)\]Selective agonists--[sobetirome](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2639) (p*K* ~d~ 10.2) \[[27](http://www.ncbi.nlm.nih.gov/pubmed/9653548?dopt=AbstractPlus), [133](http://www.ncbi.nlm.nih.gov/pubmed/269396?dopt=AbstractPlus)\]

Comments {#bph13352-sec-0007}
--------

An interaction with integrin αVβ3 has been suggested to underlie plasma membrane localization of TRs and non‐genomic signalling \[[9](http://www.ncbi.nlm.nih.gov/pubmed/15802494?dopt=AbstractPlus)\].One splice variant, TRα~2~, lacks a functional DNA‐binding domain and appears to act as a transcription suppressor.

Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.

Further Reading {#bph13352-sec-0008}
---------------

Bianco AC. (2011) Minireview: cracking the metabolic code for thyroid hormone signaling. *Endocrinology* **152**: 3306‐11 [\[PMID:21712363\]](http://www.ncbi.nlm.nih.gov/pubmed/21712363?dopt=AbstractPlus)

Brent GA. (2012) Mechanisms of thyroid hormone action. *J. Clin. Invest.* **122**: 3035‐43 [\[PMID:22945636\]](http://www.ncbi.nlm.nih.gov/pubmed/22945636?dopt=AbstractPlus)

Flamant F *et al*. (2006) International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. *Pharmacol. Rev.* **58**: 705‐11 [\[PMID:17132849\]](http://www.ncbi.nlm.nih.gov/pubmed/17132849?dopt=AbstractPlus)

Pramfalk C *et al*. (2011) Role of thyroid receptor β in lipid metabolism. *Biochim. Biophys. Acta* **1812**: 929‐37 [\[PMID:21194564\]](http://www.ncbi.nlm.nih.gov/pubmed/21194564?dopt=AbstractPlus)

Sirakov M *et al*. (2011) The thyroid hormones and their nuclear receptors in the gut: from developmental biology to cancer. *Biochim. Biophys. Acta* **1812**: 938‐46 [\[PMID:21194566\]](http://www.ncbi.nlm.nih.gov/pubmed/21194566?dopt=AbstractPlus)

Tancevski I *et al*. (2011) Thyromimetics: a journey from bench to bed‐side. *Pharmacol. Ther.* **131**: 33‐9 [\[PMID:21504761\]](http://www.ncbi.nlm.nih.gov/pubmed/21504761?dopt=AbstractPlus)

[1B. Retinoic acid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=85) {#bph13352-sec-0009}
=======================================================================================================

Overview {#bph13352-sec-0010}
--------

Retinoic acid receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**46**](http://www.ncbi.nlm.nih.gov/pubmed/17132850?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR1B family activated by the vitamin A‐derived agonists [tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) (ATRA) and [alitretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645), and the RAR‐selective synthetic agonists [TTNPB](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2646) and [adapalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429). [BMS493](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2641) is a family‐selective antagonist \[[47](http://www.ncbi.nlm.nih.gov/pubmed/19477412?dopt=AbstractPlus)\]. Nomenclature[Retinoic acid receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=590)[Retinoic acid receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=591)[Retinoic acid receptor‐γ](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=592)Systematic nomenclatureNR1B1NR1B2NR1B3HGNC, UniProt[RARA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9864), [P10276](http://www.uniprot.org/uniprot/P10276)[RARB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9865), [P10826](http://www.uniprot.org/uniprot/P10826)[RARG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9866), [P13631](http://www.uniprot.org/uniprot/P13631)Agonists[tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) (pEC~50~ 7.8) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\][tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) (pEC~50~ 7.9) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\][tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) (pEC~50~ 9.7) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\](Sub)family‐selective agonists[tazarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952) (pEC~50~ 7.2) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\][tazarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952) (pEC~50~ 9.1) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\], [adapalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429) (p*K* ~i~ 7.5) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus)\][tazarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6952) (pEC~50~ 7.4) \[[26](http://www.ncbi.nlm.nih.gov/pubmed/19058965?dopt=AbstractPlus)\], [adapalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5429) (p*K* ~i~ 6.9) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus)\]Selective agonists[BMS753](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2650) (p*K* ~i~ 8.7) \[[53](http://www.ncbi.nlm.nih.gov/pubmed/10421757?dopt=AbstractPlus)\], [Ro 40‐6055](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2647) (p*K* ~d~ 8.2) \[[33](http://www.ncbi.nlm.nih.gov/pubmed/1656191?dopt=AbstractPlus)\], [tamibarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2648) (pIC~50~ 6.9) \[[65](http://www.ncbi.nlm.nih.gov/pubmed/3184125?dopt=AbstractPlus), [108](http://www.ncbi.nlm.nih.gov/pubmed/7791761?dopt=AbstractPlus), [146](http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus)\][AC261066](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4054) (pEC~50~ 7.9--8.1) \[[90](http://www.ncbi.nlm.nih.gov/pubmed/16302793?dopt=AbstractPlus)\], [AC55649](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4055) (pEC~50~ 6.5--7.3) \[[90](http://www.ncbi.nlm.nih.gov/pubmed/16302793?dopt=AbstractPlus)\][AHPN](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3431) (p*K* ~i~ 7.1) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/8544175?dopt=AbstractPlus)\]Selective antagonists[Ro 41‐5253](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2642) (pIC~50~ 6.3--7.2) \[[2](http://www.ncbi.nlm.nih.gov/pubmed/1323127?dopt=AbstractPlus), [70](http://www.ncbi.nlm.nih.gov/pubmed/8264595?dopt=AbstractPlus)\]--[MM 11253](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4062) \[[77](http://www.ncbi.nlm.nih.gov/pubmed/10723137?dopt=AbstractPlus)\]

Comments {#bph13352-sec-0011}
--------

[Ro 41‐5253](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2642) has been suggested to be a PPARγ agonist \[[131](http://www.ncbi.nlm.nih.gov/pubmed/17290005?dopt=AbstractPlus)\]. [LE135](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3433) is an antagonist with selectivity for RARα and RARβ compared with RARγ\[[85](http://www.ncbi.nlm.nih.gov/pubmed/10331664?dopt=AbstractPlus)\].

Further Reading {#bph13352-sec-0012}
---------------

Bour G *et al*. (2007) Protein kinases and the proteasome join in the combinatorial control of transcription by nuclear retinoic acid receptors. *Trends Cell Biol.* **17**: 302‐9 [\[PMID:17467991\]](http://www.ncbi.nlm.nih.gov/pubmed/17467991?dopt=AbstractPlus)

Duong V *et al*. (2011) The molecular physiology of nuclear retinoic acid receptors. From health to disease. *Biochim. Biophys. Acta* **1812**: 1023‐31 [\[PMID:20970498\]](http://www.ncbi.nlm.nih.gov/pubmed/20970498?dopt=AbstractPlus)

Germain P *et al*. (2006) International Union of Pharmacology. LX. Retinoic acid receptors. *Pharmacol. Rev.* **58**: 712‐25 [\[PMID:17132850\]](http://www.ncbi.nlm.nih.gov/pubmed/17132850?dopt=AbstractPlus)

Maden M. (2007) Retinoic acid in the development, regeneration and maintenance of the nervous system. *Nat. Rev. Neurosci.* **8**: 755‐65 [\[PMID:17882253\]](http://www.ncbi.nlm.nih.gov/pubmed/17882253?dopt=AbstractPlus)

Mark M *et al*. (2006) Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. *Annu. Rev. Pharmacol. Toxicol.* **46**: 451‐80 [\[PMID:16402912\]](http://www.ncbi.nlm.nih.gov/pubmed/16402912?dopt=AbstractPlus)

[1C. Peroxisome proliferator‐activated receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=86) {#bph13352-sec-0013}
===========================================================================================================================

Overview {#bph13352-sec-0014}
--------

Peroxisome proliferator‐activated receptors (**PPARs, nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors**\[[**101**](http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR1C family, with diverse roles regulating lipid homeostasis, cellular differentiation, proliferation and the immune response. PPARs have many potential endogenous agonists \[[14](http://www.ncbi.nlm.nih.gov/pubmed/12749590?dopt=AbstractPlus), [101](http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus)\], including [15‐deoxy‐*Δ*^12,14^‐PGJ~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1877), prostacyclin ([PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)), many fatty acids and their oxidation products, lysophosphatidic acid ([LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906)) \[[98](http://www.ncbi.nlm.nih.gov/pubmed/12502787?dopt=AbstractPlus)\], [13‐HODE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5426), [15S‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401), [Paz‐PC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5427), [azelaoyl‐PAF](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5428) and leukotriene B4 ([LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487)). [Bezafibrate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2668) acts as a non‐selective agonist for the PPAR family \[[159](http://www.ncbi.nlm.nih.gov/pubmed/10691680?dopt=AbstractPlus)\]. These receptors also bind hypolipidaemic drugs (PPARα) and anti‐diabetic thiazolidinediones (PPARγ), as well as many non‐steroidal anti‐inflammatory drugs, such as [sulindac](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5425) and [indomethacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909). Once activated by a ligand, the receptor forms a heterodimer with members of the retinoid X receptor family and can act as a transcription factor. Although radioligand binding assays have been described for all three receptors, the radioligands are not commercially available. Commonly, receptor occupancy studies are conducted using fluorescent ligands and truncated forms of the receptor limited to the ligand binding domain. Nomenclature[Peroxisome proliferator‐activated receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593)[Peroxisome proliferator‐activated receptor‐β/δ](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=594)[Peroxisome proliferator‐activated receptor‐γ](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=595)Systematic nomenclatureNR1C1NR1C2NR1C3HGNC, UniProt[PPARA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9232), [Q07869](http://www.uniprot.org/uniprot/Q07869)[PPARD](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9235), [Q03181](http://www.uniprot.org/uniprot/Q03181)[PPARG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9236), [P37231](http://www.uniprot.org/uniprot/P37231)Agonists----[mesalazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2700) (pIC~50~ 1.8) \[[126](http://www.ncbi.nlm.nih.gov/pubmed/15824083?dopt=AbstractPlus)\]Selective agonists[GW7647](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2674) (pEC~50~ 8.2) \[[18](http://www.ncbi.nlm.nih.gov/pubmed/10389847?dopt=AbstractPlus), [19](http://www.ncbi.nlm.nih.gov/pubmed/11354382?dopt=AbstractPlus)\], [CP‐775146](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6691) (pEC~50~ 7.3) \[[68](http://www.ncbi.nlm.nih.gov/pubmed/18971326?dopt=AbstractPlus)\], [pirinixic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2666) (pEC~50~ 5.3) \[[159](http://www.ncbi.nlm.nih.gov/pubmed/10691680?dopt=AbstractPlus)\], [gemfibrozil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3439) (pEC~50~ 4.2) \[[31](http://www.ncbi.nlm.nih.gov/pubmed/21889235?dopt=AbstractPlus)\], [ciprofibrate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3438)[GW0742X](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2686) (pIC~50~ 9) \[[50](http://www.ncbi.nlm.nih.gov/pubmed/15939051?dopt=AbstractPlus), [144](http://www.ncbi.nlm.nih.gov/pubmed/12699745?dopt=AbstractPlus)\], [GW501516](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2687) (pEC~50~ 9) \[[113](http://www.ncbi.nlm.nih.gov/pubmed/11309497?dopt=AbstractPlus)\][GW1929](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2703) (p*K* ~i~ 8.8) \[[18](http://www.ncbi.nlm.nih.gov/pubmed/10389847?dopt=AbstractPlus)\], [bardoxolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2717) (Partial agonist) (p*K* ~i~ 8) \[[153](http://www.ncbi.nlm.nih.gov/pubmed/11043571?dopt=AbstractPlus)\], [rosiglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056) (p*K* ~d~ 7.4) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus), [81](http://www.ncbi.nlm.nih.gov/pubmed/9013583?dopt=AbstractPlus), [165](http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus)\], [rosiglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1056) (p*K* ~i~ 6.9) \[[88](http://www.ncbi.nlm.nih.gov/pubmed/11720854?dopt=AbstractPlus)\], [troglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2693) (pIC~50~ 6.3) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus), [165](http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus)\], [pioglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2694) (pIC~50~ 6.2) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus), [129](http://www.ncbi.nlm.nih.gov/pubmed/11095972?dopt=AbstractPlus), [165](http://www.ncbi.nlm.nih.gov/pubmed/9454824?dopt=AbstractPlus)\], [troglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2693) (p*K* ~i~ 5.8) \[[8](http://www.ncbi.nlm.nih.gov/pubmed/8828476?dopt=AbstractPlus)\], [ciglitazone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2711) (pEC~50~ 4.6) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/9836620?dopt=AbstractPlus)\]Selective antagonists[GW6471](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3440) (pIC~50~ 6.6) \[[162](http://www.ncbi.nlm.nih.gov/pubmed/11845213?dopt=AbstractPlus)\][GSK0660](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3441) (pIC~50~ 6.5) \[[134](http://www.ncbi.nlm.nih.gov/pubmed/17975020?dopt=AbstractPlus)\][T0070907](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3444) (p*K* ~i~ 9) \[[78](http://www.ncbi.nlm.nih.gov/pubmed/11877444?dopt=AbstractPlus)\], [GW9662](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3442) (Irreversible inhibition) (pIC~50~ 8.1) \[[79](http://www.ncbi.nlm.nih.gov/pubmed/12022867?dopt=AbstractPlus)\], [CDDO‐Me](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3443) (p*K* ~i~ 6.9) \[[153](http://www.ncbi.nlm.nih.gov/pubmed/11043571?dopt=AbstractPlus)\]

Comments {#bph13352-sec-0015}
--------

As with the estrogen receptor antagonists, many agents show tissue‐selective efficacy (*e.g*. \[[13](http://www.ncbi.nlm.nih.gov/pubmed/11030710?dopt=AbstractPlus), [110](http://www.ncbi.nlm.nih.gov/pubmed/11991651?dopt=AbstractPlus), [125](http://www.ncbi.nlm.nih.gov/pubmed/11684010?dopt=AbstractPlus)\]). Agonists with mixed activity at PPARα and PPARγ have also been described (*e.g* \[[35](http://www.ncbi.nlm.nih.gov/pubmed/15120604?dopt=AbstractPlus), [52](http://www.ncbi.nlm.nih.gov/pubmed/14701675?dopt=AbstractPlus), [163](http://www.ncbi.nlm.nih.gov/pubmed/15115385?dopt=AbstractPlus)\]).

Further Reading {#bph13352-sec-0016}
---------------

Huang JV *et al*. (2012) PPAR‐γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. *J. Lipid Res.* **53**: 1738‐54 [\[PMID:22685322\]](http://www.ncbi.nlm.nih.gov/pubmed/22685322?dopt=AbstractPlus)

Michalik L *et al*. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator‐activated receptors. *Pharmacol. Rev.* **58**: 726‐41 [\[PMID:17132851\]](http://www.ncbi.nlm.nih.gov/pubmed/17132851?dopt=AbstractPlus)

Michalik L *et al*. (2008) PPARs Mediate Lipid Signaling in Inflammation and Cancer. *PPAR Res* **2008**: 134059 [\[PMID:19125181\]](http://www.ncbi.nlm.nih.gov/pubmed/19125181?dopt=AbstractPlus)

Peters JM *et al*. (2012) The role of peroxisome proliferator‐activated receptors in carcinogenesis and chemoprevention. *Nat. Rev. Cancer* **12**: 181‐95 [\[PMID:22318237\]](http://www.ncbi.nlm.nih.gov/pubmed/22318237?dopt=AbstractPlus)

Pirat C *et al*. (2012) Targeting peroxisome proliferator‐activated receptors (PPARs): development of modulators. *J. Med. Chem.* **55**: 4027‐61 [\[PMID:22260081\]](http://www.ncbi.nlm.nih.gov/pubmed/22260081?dopt=AbstractPlus)

Varga T *et al*. (2011) PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. *Biochim. Biophys. Acta* **1812**: 1007‐22 [\[PMID:21382489\]](http://www.ncbi.nlm.nih.gov/pubmed/21382489?dopt=AbstractPlus)

Youssef J *et al*. (2011) Peroxisome proliferator‐activated receptors and cancer: challenges and opportunities. *Br. J. Pharmacol.* **164**: 68‐82 [\[PMID:21449912\]](http://www.ncbi.nlm.nih.gov/pubmed/21449912?dopt=AbstractPlus)

[1D. Rev‐Erb receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=87) {#bph13352-sec-0017}
=================================================================================================

Overview {#bph13352-sec-0018}
--------

Rev‐erb receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand, but are thought to be activated by heme. Nomenclature[Rev‐Erb‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=596)[Rev‐Erb‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=597)Systematic nomenclatureNR1D1NR1D2HGNC, UniProt[NR1D1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7962), [P20393](http://www.uniprot.org/uniprot/P20393)[NR1D2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7963), [Q14995](http://www.uniprot.org/uniprot/Q14995)Endogenous agonists[heme](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349) (Selective) \[[122](http://www.ncbi.nlm.nih.gov/pubmed/18037887?dopt=AbstractPlus), [164](http://www.ncbi.nlm.nih.gov/pubmed/18006707?dopt=AbstractPlus)\][heme](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349) (Selective) \[[122](http://www.ncbi.nlm.nih.gov/pubmed/18037887?dopt=AbstractPlus), [164](http://www.ncbi.nlm.nih.gov/pubmed/18006707?dopt=AbstractPlus)\]Selective agonists[GSK4112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2903) (pEC~50~ 6.4) \[[51](http://www.ncbi.nlm.nih.gov/pubmed/20677822?dopt=AbstractPlus)\], [GSK4112](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2903) (pIC~50~ 5.6) \[[73](http://www.ncbi.nlm.nih.gov/pubmed/21043485?dopt=AbstractPlus)\]--Selective antagonists[SR8278](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2904) (pIC~50~ 6.5) \[[73](http://www.ncbi.nlm.nih.gov/pubmed/21043485?dopt=AbstractPlus)\]--

Further Reading {#bph13352-sec-0019}
---------------
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Phelan CA *et al*. (2010) Structure of Rev‐erbalpha bound to N‐CoR reveals a unique mechanism of nuclear receptor‐co‐repressor interaction. *Nat. Struct. Mol. Biol.* **17**: 808‐14 [\[PMID:20581824\]](http://www.ncbi.nlm.nih.gov/pubmed/20581824?dopt=AbstractPlus)

Sladek FM. (2011) What are nuclear receptor ligands? *Mol. Cell. Endocrinol.* **334**: 3‐13 [\[PMID:20615454\]](http://www.ncbi.nlm.nih.gov/pubmed/20615454?dopt=AbstractPlus)

Yin L *et al*. (2010) Nuclear receptor Rev‐erbalpha: a heme receptor that coordinates circadian rhythm and metabolism. *Nucl Recept Signal* **8**: e001 [\[PMID:20414452\]](http://www.ncbi.nlm.nih.gov/pubmed/20414452?dopt=AbstractPlus)

[1F. Retinoic acid‐related orphans](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=88) {#bph13352-sec-0020}
=============================================================================================================

Overview {#bph13352-sec-0021}
--------

Retinoic acid receptor‐related orphan receptors (ROR, **nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be assigned a definitive endogenous ligand, although RORα may be synthesized with a 'captured' agonist such as [cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718)\[[66](http://www.ncbi.nlm.nih.gov/pubmed/14722075?dopt=AbstractPlus), [67](http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus)\]. Nomenclature[RAR‐related orphan receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=598)[RAR‐related orphan receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=599)[RAR‐related orphan receptor‐γ](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=600)Systematic nomenclatureNR1F1NR1F2NR1F3HGNC, UniProt[RORA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10258), [P35398](http://www.uniprot.org/uniprot/P35398)[RORB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10259), [Q92753](http://www.uniprot.org/uniprot/Q92753)[RORC](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10260), [P51449](http://www.uniprot.org/uniprot/P51449)Endogenous agonists[cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718) (Selective) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus), [115](http://www.ncbi.nlm.nih.gov/pubmed/8858107?dopt=AbstractPlus)\]----Selective agonists[7‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3432) \[[15](http://www.ncbi.nlm.nih.gov/pubmed/14622968?dopt=AbstractPlus)\], [cholesterol sulphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2738) \[[15](http://www.ncbi.nlm.nih.gov/pubmed/14622968?dopt=AbstractPlus), [67](http://www.ncbi.nlm.nih.gov/pubmed/12467577?dopt=AbstractPlus)\]----

Comments {#bph13352-sec-0022}
--------

[tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) shows selectivity for RORβ within the ROR family \[[139](http://www.ncbi.nlm.nih.gov/pubmed/12958591?dopt=AbstractPlus)\]. RORα has been suggested to be a nuclear receptor responding to [melatonin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224)\[[158](http://www.ncbi.nlm.nih.gov/pubmed/7885826?dopt=AbstractPlus)\].

Further Reading {#bph13352-sec-0023}
---------------

Benoit G *et al*. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. *Pharmacol. Rev.* **58**: 798‐836 [\[PMID:17132856\]](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)

[1H. Liver X receptor‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=89) {#bph13352-sec-0024}
===============================================================================================================

Overview {#bph13352-sec-0025}
--------

Liver X and farnesoid X receptors (LXR and FXR, **nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors**\[[**105**](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)\]) are members of a steroid analogue‐activated nuclear receptor subfamily, which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs appear to be activated by bile acids. Nomenclature[Farnesoid X receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=603)[Farnesoid X receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=604)[Liver X receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=602)[Liver X receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=601)Systematic nomenclatureNR1H4NR1H5NR1H3NR1H2HGNC, UniProt[NR1H4](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7967), [Q96RI1](http://www.uniprot.org/uniprot/Q96RI1)[NR1H5P](http://www.genenames.org/data/hgnc_data.php?hgnc_id=32673), --[NR1H3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7966), [Q13133](http://www.uniprot.org/uniprot/Q13133)[NR1H2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7965), [P55055](http://www.uniprot.org/uniprot/P55055)Potency order[chenodeoxycholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=608)\>[lithocholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611), [deoxycholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=610) \[[93](http://www.ncbi.nlm.nih.gov/pubmed/10334992?dopt=AbstractPlus), [116](http://www.ncbi.nlm.nih.gov/pubmed/10334993?dopt=AbstractPlus)\]--[20S‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3434), [22R‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2742), [24(S)‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750)\>[25‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2885), [27‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752) \[[80](http://www.ncbi.nlm.nih.gov/pubmed/9013544?dopt=AbstractPlus)\][20S‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3434), [22R‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2742), [24(S)‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750)\>[25‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2885), [27‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752) \[[80](http://www.ncbi.nlm.nih.gov/pubmed/9013544?dopt=AbstractPlus)\]Endogenous agonists--[lanosterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746) (pEC~50~ 6) \[[114](http://www.ncbi.nlm.nih.gov/pubmed/12529392?dopt=AbstractPlus)\] -- Mouse----Selective agonists[GW4064](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2743) (pEC~50~ 7.8) \[[95](http://www.ncbi.nlm.nih.gov/pubmed/10956205?dopt=AbstractPlus)\], [obeticholic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3435) (pEC~50~ 7) \[[117](http://www.ncbi.nlm.nih.gov/pubmed/12166927?dopt=AbstractPlus)\], [fexaramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2744) (pEC~50~ 6.6) \[[36](http://www.ncbi.nlm.nih.gov/pubmed/12718892?dopt=AbstractPlus)\]------Selective antagonists[guggulsterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2745) (pIC~50~ 5.7--6) \[[161](http://www.ncbi.nlm.nih.gov/pubmed/12089353?dopt=AbstractPlus)\]------

Comments {#bph13352-sec-0026}
--------

[T0901317](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2755)\[[123](http://www.ncbi.nlm.nih.gov/pubmed/10968783?dopt=AbstractPlus)\] and [GW3965](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2754)\[[28](http://www.ncbi.nlm.nih.gov/pubmed/11985463?dopt=AbstractPlus)\] are synthetic agonists acting at both LXRα and LXRβ with less than 10‐fold selectivity.

Further Reading {#bph13352-sec-0027}
---------------
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Claudel T *et al*. (2011) Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. *Biochim. Biophys. Acta* **1812**: 867‐78 [\[PMID:21194565\]](http://www.ncbi.nlm.nih.gov/pubmed/21194565?dopt=AbstractPlus)
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Gardmo C *et al*. (2011) Proteomics for the discovery of nuclear bile acid receptor FXR targets. *Biochim. Biophys. Acta* **1812**: 836‐41 [\[PMID:21439373\]](http://www.ncbi.nlm.nih.gov/pubmed/21439373?dopt=AbstractPlus)

Kemper JK. (2011) Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post‐translational modifications. *Biochim. Biophys. Acta* **1812**: 842‐50 [\[PMID:21130162\]](http://www.ncbi.nlm.nih.gov/pubmed/21130162?dopt=AbstractPlus)

Matsubara T *et al*. (2013) FXR signaling in the enterohepatic system. *Mol. Cell. Endocrinol.* **368**: 17‐29 [\[PMID:22609541\]](http://www.ncbi.nlm.nih.gov/pubmed/22609541?dopt=AbstractPlus)

Moore DD *et al*. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors: constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. *Pharmacol. Rev.* **58**: 742‐59 [\[PMID:17132852\]](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)

[1I. Vitamin D receptor‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=90) {#bph13352-sec-0028}
=================================================================================================================

Overview {#bph13352-sec-0029}
--------

Vitamin D (VDR), Pregnane X (PXR) and Constitutive Androstane (CAR) receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors**\[[**105**](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)\]) are members of the NR1I family of nuclear receptors, which form heterodimers with members of the retinoid X receptor family. PXR and CAR are activated by a range of exogenous compounds, with no established endogenous physiological agonists, although high concentrations of bile acids and bile pigments activate PXR and CAR \[[105](http://www.ncbi.nlm.nih.gov/pubmed/17132852?dopt=AbstractPlus)\]. Nomenclature[Vitamin D receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=605)[Pregnane X receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=606)[Constitutive androstane receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=607)Systematic nomenclatureNR1I1NR1I2NR1I3HGNC, UniProt[VDR](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12679), [P11473](http://www.uniprot.org/uniprot/P11473)[NR1I2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7968), [O75469](http://www.uniprot.org/uniprot/O75469)[NR1I3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7969), [Q14994](http://www.uniprot.org/uniprot/Q14994)Endogenous agonists[1,25‐dihydroxyvitamin D3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779) (p*K* ~d~ 8.9--9.2) \[[12](http://www.ncbi.nlm.nih.gov/pubmed/7976510?dopt=AbstractPlus), [39](http://www.ncbi.nlm.nih.gov/pubmed/12089348?dopt=AbstractPlus)\][17β‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013) (Selective) \[[64](http://www.ncbi.nlm.nih.gov/pubmed/10628745?dopt=AbstractPlus)\]--Selective agonists[seocalcitol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2777) (p*K* ~d~ 9.6) \[[29](http://www.ncbi.nlm.nih.gov/pubmed/1472092?dopt=AbstractPlus), [157](http://www.ncbi.nlm.nih.gov/pubmed/8573413?dopt=AbstractPlus)\], [doxercalciferol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2790)[hyperforin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2764) (pEC~50~ 7.6) \[[106](http://www.ncbi.nlm.nih.gov/pubmed/10852961?dopt=AbstractPlus), [156](http://www.ncbi.nlm.nih.gov/pubmed/10974665?dopt=AbstractPlus)\], [5β‐pregnane‐3,20‐dione](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2759) (pIC~50~ 6.4) \[[64](http://www.ncbi.nlm.nih.gov/pubmed/10628745?dopt=AbstractPlus)\], [lovastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739) (pEC~50~ 5.3--6) \[[82](http://www.ncbi.nlm.nih.gov/pubmed/9727070?dopt=AbstractPlus)\], [rifampicin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765) (pEC~50~ 5.5--6) \[[16](http://www.ncbi.nlm.nih.gov/pubmed/9784494?dopt=AbstractPlus), [82](http://www.ncbi.nlm.nih.gov/pubmed/9727070?dopt=AbstractPlus)\][TCPOBOP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2756) (pEC~50~ 7.7) \[[149](http://www.ncbi.nlm.nih.gov/pubmed/10757780?dopt=AbstractPlus)\] -- Mouse, [CITCO](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2758) (pEC~50~ 7.3) \[[92](http://www.ncbi.nlm.nih.gov/pubmed/12611900?dopt=AbstractPlus)\]Selective antagonists[TEI‐9647](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2788) (pIC~50~ 8.2) \[[128](http://www.ncbi.nlm.nih.gov/pubmed/17125259?dopt=AbstractPlus)\] -- Chicken, [ZK159222](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2789) (pIC~50~ 7.5) \[[42](http://www.ncbi.nlm.nih.gov/pubmed/12901907?dopt=AbstractPlus), [60](http://www.ncbi.nlm.nih.gov/pubmed/11094341?dopt=AbstractPlus)\]----Comments----[clotrimazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2330) \[[107](http://www.ncbi.nlm.nih.gov/pubmed/10748001?dopt=AbstractPlus)\] and [T0901317](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2755) \[[69](http://www.ncbi.nlm.nih.gov/pubmed/23665929?dopt=AbstractPlus)\] although acting at other sites, function as antagonists of the constitutive androstane receptor.
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---------------
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[2A. Hepatocyte nuclear factor‐4 receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=91) {#bph13352-sec-0031}
=====================================================================================================================

Overview {#bph13352-sec-0032}
--------

The nomenclature of hepatocyte nuclear factor‐4 receptors is agreed by the [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]. While linoleic acid has been identified as the endogenous ligand for HNF4α its function remains ambiguous \[[167](http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus)\]. HNF4γ has yet to be paired with an endogenous ligand. Nomenclature[Hepatocyte nuclear factor‐4‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=608)[Hepatocyte nuclear factor‐4‐γ](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=609)Systematic nomenclatureNR2A1NR2A2HGNC, UniProt[HNF4A](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5024), [P41235](http://www.uniprot.org/uniprot/P41235)[HNF4G](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5026), [Q14541](http://www.uniprot.org/uniprot/Q14541)Endogenous agonists[linoleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052) (Selective) \[[167](http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus)\]--Selective antagonists[BI6015](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6695) \[[72](http://www.ncbi.nlm.nih.gov/pubmed/22840769?dopt=AbstractPlus)\]--CommentsHNF4α has constitutive transactivation activity \[[167](http://www.ncbi.nlm.nih.gov/pubmed/19440305?dopt=AbstractPlus)\] and binds DNA as a homodimer \[[63](http://www.ncbi.nlm.nih.gov/pubmed/7651430?dopt=AbstractPlus)\].--
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[2B. Retinoid X receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=92) {#bph13352-sec-0034}
====================================================================================================

Overview {#bph13352-sec-0035}
--------

Retinoid X receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**45**](http://www.ncbi.nlm.nih.gov/pubmed/17132853?dopt=AbstractPlus)\]) are NR2B family members activated by [alitretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2645) and the RXR‐selective agonists [bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) and [LG100268](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2808), sometimes referred to as rexinoids. [UVI3003](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2816)\[[109](http://www.ncbi.nlm.nih.gov/pubmed/17947383?dopt=AbstractPlus)\] and [HX 531](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8079) \[[37](http://www.ncbi.nlm.nih.gov/pubmed/10748721?dopt=AbstractPlus)\] have been described as a pan‐RXR antagonists. These receptors form RXR‐RAR heterodimers and RXR‐RXR homodimers \[[23](http://www.ncbi.nlm.nih.gov/pubmed/8801176?dopt=AbstractPlus), [97](http://www.ncbi.nlm.nih.gov/pubmed/8521508?dopt=AbstractPlus)\]. Nomenclature[Retinoid X receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=610)[Retinoid X receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=611)[Retinoid X receptor‐γ](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=612)Systematic nomenclatureNR2B1NR2B2NR2B3HGNC, UniProt[RXRA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10477), [P19793](http://www.uniprot.org/uniprot/P19793)[RXRB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10478), [P28702](http://www.uniprot.org/uniprot/P28702)[RXRG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10479), [P48443](http://www.uniprot.org/uniprot/P48443)(Sub)family‐selective agonists[bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) (pIC~50~ 7.4) \[[17](http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus), [22](http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus), [146](http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus)\][bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) (pIC~50~ 7.7) \[[17](http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus), [22](http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus), [146](http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus)\][bexarotene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2807) (pIC~50~ 7.5) \[[17](http://www.ncbi.nlm.nih.gov/pubmed/8071941?dopt=AbstractPlus), [22](http://www.ncbi.nlm.nih.gov/pubmed/10052980?dopt=AbstractPlus), [146](http://www.ncbi.nlm.nih.gov/pubmed/10637371?dopt=AbstractPlus)\]Selective agonists[CD3254](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2810) (pIC~50~ 8.5) \[[48](http://www.ncbi.nlm.nih.gov/pubmed/11805839?dopt=AbstractPlus)\]----
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[2C. Testicular receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=93) {#bph13352-sec-0037}
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Overview {#bph13352-sec-0038}
--------

Testicular receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand, although testicular receptor 4 has been reported to respond to retinoids. Nomenclature[Testicular receptor 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=613)[Testicular receptor 4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=614)Systematic nomenclatureNR2C1NR2C2HGNC, UniProt[NR2C1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7971), [P13056](http://www.uniprot.org/uniprot/P13056)[NR2C2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7972), [P49116](http://www.uniprot.org/uniprot/P49116)Endogenous agonists--[retinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053) (Selective) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/21068381?dopt=AbstractPlus)\], [tretinoin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2644) (Selective) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/21068381?dopt=AbstractPlus)\]CommentsForms a heterodimer with TR4; gene disruption appears without effect on testicular development or function \[[135](http://www.ncbi.nlm.nih.gov/pubmed/12052874?dopt=AbstractPlus)\].Forms a heterodimer with TR2.
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[2E. Tailless‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=94) {#bph13352-sec-0040}
=======================================================================================================

Overview {#bph13352-sec-0041}
--------

Tailless‐like receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand. Nomenclature[TLX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=615)[PNR](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=616)Systematic nomenclatureNR2E1NR2E3HGNC, UniProt[NR2E1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7973), [Q9Y466](http://www.uniprot.org/uniprot/Q9Y466)[NR2E3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7974), [Q9Y5X4](http://www.uniprot.org/uniprot/Q9Y5X4)CommentsGene disruption is associated with abnormal brain development \[[76](http://www.ncbi.nlm.nih.gov/pubmed/12902391?dopt=AbstractPlus), [104](http://www.ncbi.nlm.nih.gov/pubmed/9394001?dopt=AbstractPlus)\].--
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[2F. COUP‐TF‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=95) {#bph13352-sec-0043}
======================================================================================================

Overview {#bph13352-sec-0044}
--------

COUP‐TF‐like receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand. Nomenclature[COUP‐TF1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=617)[COUP‐TF2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=618)[V‐erbA‐related gene](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=619)Systematic nomenclatureNR2F1NR2F2NR2F6HGNC, UniProt[NR2F1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7975), [P10589](http://www.uniprot.org/uniprot/P10589)[NR2F2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7976), [P24468](http://www.uniprot.org/uniprot/P24468)[NR2F6](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7977), [P10588](http://www.uniprot.org/uniprot/P10588)CommentsGene disruption is perinatally lethal \[[121](http://www.ncbi.nlm.nih.gov/pubmed/9271116?dopt=AbstractPlus)\].Gene disruption is embryonically lethal \[[118](http://www.ncbi.nlm.nih.gov/pubmed/10215630?dopt=AbstractPlus)\].Gene disruption impairs CNS development \[[155](http://www.ncbi.nlm.nih.gov/pubmed/15741322?dopt=AbstractPlus)\].
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[3B. Estrogen‐related receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=97) {#bph13352-sec-0046}
==========================================================================================================

Overview {#bph13352-sec-0047}
--------

Estrogen‐related receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand. Nomenclature[Estrogen‐related receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622)[Estrogen‐related receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=623)[Estrogen‐related receptor‐γ](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=624)Systematic nomenclatureNR3B1NR3B2NR3B3HGNC, UniProt[ESRRA](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3471), [P11474](http://www.uniprot.org/uniprot/P11474)[ESRRB](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3473), [O95718](http://www.uniprot.org/uniprot/O95718)[ESRRG](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3474), [P62508](http://www.uniprot.org/uniprot/P62508)CommentsActivated by some dietary flavonoids \[[141](http://www.ncbi.nlm.nih.gov/pubmed/14638870?dopt=AbstractPlus)\]; activated by the syntheticagonist [GSK4716](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2835) \[[176](http://www.ncbi.nlm.nih.gov/pubmed/15857113?dopt=AbstractPlus)\] and blocked by [XCT790](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2832) \[[160](http://www.ncbi.nlm.nih.gov/pubmed/15184675?dopt=AbstractPlus)\].May be activated by [DY131](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834) \[[166](http://www.ncbi.nlm.nih.gov/pubmed/15713377?dopt=AbstractPlus)\].May be activated by [DY131](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2834) \[[166](http://www.ncbi.nlm.nih.gov/pubmed/15713377?dopt=AbstractPlus)\].
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[4A. Nerve growth factor IB‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=99) {#bph13352-sec-0049}
=====================================================================================================================

Overview {#bph13352-sec-0050}
--------

Nerve growth factor IB‐like receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand. Nomenclature[Nerve Growth factor IB](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=629)[Nuclear receptor related 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=630)[Neuron‐derived orphan receptor 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=631)Systematic nomenclatureNR4A1NR4A2NR4A3HGNC, UniProt[NR4A1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7980), [P22736](http://www.uniprot.org/uniprot/P22736)[NR4A2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7981), [P43354](http://www.uniprot.org/uniprot/P43354)[NR4A3](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7982), [Q92570](http://www.uniprot.org/uniprot/Q92570)CommentsAn endogenous agonist, [cytosporone B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5424), has been described \[[168](http://www.ncbi.nlm.nih.gov/pubmed/18690216?dopt=AbstractPlus)\], although structural analysis and molecular modelling has not identified a ligand binding site \[[4](http://www.ncbi.nlm.nih.gov/pubmed/12809604?dopt=AbstractPlus), [40](http://www.ncbi.nlm.nih.gov/pubmed/15716272?dopt=AbstractPlus), [154](http://www.ncbi.nlm.nih.gov/pubmed/12774125?dopt=AbstractPlus)\].----
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===============================================================================================================

Overview {#bph13352-sec-0053}
--------

Fushi tarazu F1‐like receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand. Nomenclature[Steroidogenic factor 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=632)[Liver receptor homolog‐1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=633)Systematic nomenclatureNR5A1NR5A2HGNC, UniProt[NR5A1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7983), [Q13285](http://www.uniprot.org/uniprot/Q13285)[NR5A2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7984), [O00482](http://www.uniprot.org/uniprot/O00482)CommentsReported to be inhibited by [AC45594](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5422) \[[32](http://www.ncbi.nlm.nih.gov/pubmed/18055761?dopt=AbstractPlus)\] and [SID7969543](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5423) \[[91](http://www.ncbi.nlm.nih.gov/pubmed/18334597?dopt=AbstractPlus)\].--
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[6A. Germ cell nuclear factor receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=101) {#bph13352-sec-0055}
===================================================================================================================

Overview {#bph13352-sec-0056}
--------

Germ cell nuclear factor receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand. Nomenclature[Germ cell nuclear factor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=634)Systematic nomenclatureNR6A1HGNC, UniProt[NR6A1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7985), [Q15406](http://www.uniprot.org/uniprot/Q15406)
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[0B. DAX‐like receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=102) {#bph13352-sec-0058}
===================================================================================================

Overview {#bph13352-sec-0059}
--------

Dax‐like receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**7**](http://www.ncbi.nlm.nih.gov/pubmed/17132856?dopt=AbstractPlus)\]) have yet to be officially paired with an endogenous ligand. Nomenclature[DAX1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=635)[SHP](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=636)Systematic nomenclatureNR0B1NR0B2HGNC, UniProt[NR0B1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7960), [P51843](http://www.uniprot.org/uniprot/P51843)[NR0B2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7961), [Q15466](http://www.uniprot.org/uniprot/Q15466)
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[Steroid hormone receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=107) {#bph13352-sec-0061}
======================================================================================================

Overview {#bph13352-sec-0062}
--------

Steroid hormone receptors (**nomenclature as agreed by the** [**NC‐IUPHAR**]{.ul} **Subcommittee on Nuclear Hormone Receptors** \[[**30**](http://www.ncbi.nlm.nih.gov/pubmed/17132854?dopt=AbstractPlus), [**89**](http://www.ncbi.nlm.nih.gov/pubmed/17132855?dopt=AbstractPlus)\]) are nuclear hormone receptors of the NR3 class, with endogenous agonists that may be divided into 3‐hydroxysteroids ([estrone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818) and [17β‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013)) and 3‐ketosteroids ([dihydrotestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856)\[DHT\], [aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872), [cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868), [corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869), [progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) and [testosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858)). These receptors exist as dimers coupled with chaperone molecules (such as [hsp90β](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5365)([*HSP90AB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5258), [P08238](http://www.uniprot.org/uniprot/P08238)) and immunophilin FKBP52:[*FKBP4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3720), [Q02790](http://www.uniprot.org/uniprot/Q02790)), which are shed on binding the steroid hormone. Although rapid signalling phenomena are observed \[[84](http://www.ncbi.nlm.nih.gov/pubmed/18784332?dopt=AbstractPlus), [120](http://www.ncbi.nlm.nih.gov/pubmed/19389460?dopt=AbstractPlus)\], the principal signalling cascade appears to involve binding of the activated receptors to nuclear hormone response elements of the genome, with a 15‐nucleotide consensus sequence AGAACAnnnTGTTCT (*i.e.* an inverted palindrome) as homo‐ or heterodimers. They also affect transcription by protein‐protein interactions with other transcription factors, such as activator protein 1 (AP‐1) and nuclear factor *κ*B (NF‐*κ*B). Splice variants of each of these receptors can form functional or non‐functional monomers that can dimerize to form functional or non‐functional receptors. For example, alternative splicing of PR mRNA produces A and B monomers that combine to produce functional AA, AB and BB receptors with distinct characteristics \[[150](http://www.ncbi.nlm.nih.gov/pubmed/8264658?dopt=AbstractPlus)\].

A 7TM receptor responsive to estrogen ([*GPER1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4485), [Q99527](http://www.uniprot.org/uniprot/Q99527), also known as GPR30, see \[[119](http://www.ncbi.nlm.nih.gov/pubmed/18271749?dopt=AbstractPlus)\]) has been described. Human orthologues of 7TM \'membrane progestin receptors\' ([*PAQR7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23146), [*PAQR8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15708) and [*PAQR5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29645)), initially discovered in fish \[[174](http://www.ncbi.nlm.nih.gov/pubmed/12601167?dopt=AbstractPlus), [175](http://www.ncbi.nlm.nih.gov/pubmed/12574519?dopt=AbstractPlus)\], appear to localize to intracellular membranes and respond to \'non‐genomic\' progesterone analogues independently of G proteins \[[137](http://www.ncbi.nlm.nih.gov/pubmed/18603275?dopt=AbstractPlus)\].

[3A. Estrogen receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=96) {#bph13352-sec-0063}
==================================================================================================

Overview {#bph13352-sec-0064}
--------

Estrogen receptor (ER) activity regulates diverse physiological processes *via* transcriptional modulation of target genes. The selection of target genes and the magnitude of the response, be it induction or repression, are determined by many factors, including the effect of the hormone ligand and DNA binding on ER structural conformation, and the local cellular regulatory environment. The cellular environment defines the specific complement of DNA enhancer and promoter elements present and the availability of coregulators to form functional transcription complexes. Together, these determinants control the resulting biological response. Nomenclature[Estrogen receptor‐α](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620)[Estrogen receptor‐β](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621)Systematic nomenclatureNR3A1NR3A2HGNC, UniProt[ESR1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3467), [P03372](http://www.uniprot.org/uniprot/P03372)[ESR2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3468), [Q92731](http://www.uniprot.org/uniprot/Q92731)Endogenous agonists[estriol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2821) (p*K* ~i~ 8.7) \[[75](http://www.ncbi.nlm.nih.gov/pubmed/9048584?dopt=AbstractPlus)\], [estrone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818) (p*K* ~i~ 8.5) \[[75](http://www.ncbi.nlm.nih.gov/pubmed/9048584?dopt=AbstractPlus)\]--Selective agonists[propylpyrazoletriol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2819) (p*K* ~i~ 9.6) \[[74](http://www.ncbi.nlm.nih.gov/pubmed/11014206?dopt=AbstractPlus), [138](http://www.ncbi.nlm.nih.gov/pubmed/11150164?dopt=AbstractPlus)\], [ethinyl estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7071) (pIC~50~ 8.7) \[[62](http://www.ncbi.nlm.nih.gov/pubmed/16722623?dopt=AbstractPlus)\][WAY200070](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4052) (pIC~50~ 8.5--9) \[[94](http://www.ncbi.nlm.nih.gov/pubmed/15456246?dopt=AbstractPlus)\], [diarylpropionitril](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2825) (p*K* ~i~ 8.6) \[[100](http://www.ncbi.nlm.nih.gov/pubmed/11708925?dopt=AbstractPlus), [138](http://www.ncbi.nlm.nih.gov/pubmed/11150164?dopt=AbstractPlus)\], [prinaberel](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6700) (pIC~50~ 8.3) \[[94](http://www.ncbi.nlm.nih.gov/pubmed/15456246?dopt=AbstractPlus)\](Sub)family‐selective antagonists[bazedoxifene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355) (pIC~50~ 7.6) \[[103](http://www.ncbi.nlm.nih.gov/pubmed/11356100?dopt=AbstractPlus)\][bazedoxifene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7355) (pIC~50~ 7.1) \[[103](http://www.ncbi.nlm.nih.gov/pubmed/11356100?dopt=AbstractPlus)\]Selective antagonists[clomiphene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4159) (p*K* ~i~ 8.9) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [methyl‐piperidino‐pyrazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3459) (p*K* ~i~ 8.6) \[[142](http://www.ncbi.nlm.nih.gov/pubmed/11861516?dopt=AbstractPlus)\][R,R‐THC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2822) (p*K* ~i~ 8.4) \[[99](http://www.ncbi.nlm.nih.gov/pubmed/10395487?dopt=AbstractPlus), [143](http://www.ncbi.nlm.nih.gov/pubmed/9927308?dopt=AbstractPlus)\], [PHTPP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3461) (p*K* ~i~ 6.9) \[[172](http://www.ncbi.nlm.nih.gov/pubmed/17228884?dopt=AbstractPlus)\]

Comments {#bph13352-sec-0065}
--------

[R,R‐THC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2822) exhibits partial agonist activity at ERα\[[99](http://www.ncbi.nlm.nih.gov/pubmed/10395487?dopt=AbstractPlus), [143](http://www.ncbi.nlm.nih.gov/pubmed/9927308?dopt=AbstractPlus)\]. Estrogen receptors may be blocked non‐selectively by [tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016) and [raloxifene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820) and labelled by [\[^3^H\]17β‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1012) and [\[^3^H\]tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5384). Many agents thought initially to be antagonists at estrogen receptors appear to have tissue‐specific efficacy (*e.g*. [Tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016) is an antagonist at estrogen receptors in the breast, but is an agonist at estrogen receptors in the uterus), hence the descriptor SERM (selective estrogen receptor modulator) or SnuRM (selective nuclear receptor modulator). [Y134](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5430) has been suggested to be an ERα‐selective estrogen receptor modulator \[[112](http://www.ncbi.nlm.nih.gov/pubmed/17115070?dopt=AbstractPlus)\].

[3C. 3‐Ketosteroid receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=98) {#bph13352-sec-0066}
=======================================================================================================

Nomenclature[Androgen receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628)[Glucocorticoid receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=625)[Mineralocorticoid receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626)[Progesterone receptor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627)Systematic nomenclatureNR3C4NR3C1NR3C2NR3C3HGNC, UniProt[AR](http://www.genenames.org/data/hgnc_data.php?hgnc_id=644), [P10275](http://www.uniprot.org/uniprot/P10275)[NR3C1](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7978), [P04150](http://www.uniprot.org/uniprot/P04150)[NR3C2](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7979), [P08235](http://www.uniprot.org/uniprot/P08235)[PGR](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8910), [P06401](http://www.uniprot.org/uniprot/P06401)Rank order of potency[dihydrotestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856)\>[testosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858)[cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868), [corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869)≫[aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872), [deoxycortisone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450) \[[127](http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus)\][corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869), [cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868), [aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872), [progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) \[[127](http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus)\][progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377)Endogenous agonists[dihydrotestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2856) (p*K* ~d~ 9.3) \[[147](http://www.ncbi.nlm.nih.gov/pubmed/2911578?dopt=AbstractPlus)\]--[aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872) (Selective) (pIC~50~ 9.8--10) \[[58](http://www.ncbi.nlm.nih.gov/pubmed/10611474?dopt=AbstractPlus), [127](http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus)\][progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) (Selective) (pEC~50~ 8.8) \[[38](http://www.ncbi.nlm.nih.gov/pubmed/9667968?dopt=AbstractPlus)\]Agonists[methyltestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6945) (Androgen receptor promoter activity in luciferase reporter assay) (pEC~50~ 9.7) \[[1](http://www.ncbi.nlm.nih.gov/pubmed/24177288?dopt=AbstractPlus)\], [danazol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6942) (p*K* ~i~ 8) \[[24](http://www.ncbi.nlm.nih.gov/pubmed/7355922?dopt=AbstractPlus)\] -- Rat, [ethylestrenol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6948), [nandrolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6949)------Selective agonists[testosterone propionate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7100) (p*K* ~i~ 9.6) \[[96](http://www.ncbi.nlm.nih.gov/pubmed/17574413?dopt=AbstractPlus)\], [mibolerone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2859) (pIC~50~ 9) \[[49](http://www.ncbi.nlm.nih.gov/pubmed/10852459?dopt=AbstractPlus)\], [fluoxymesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2861) (p*K* ~i~ 8.2) \[[61](http://www.ncbi.nlm.nih.gov/pubmed/17439112?dopt=AbstractPlus)\], [methyltrienolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2857) (pEC~50~\<5) \[[152](http://www.ncbi.nlm.nih.gov/pubmed/10076535?dopt=AbstractPlus)\], [dromostanolone propionate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6947)[fluticasone propionate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7080) (pIC~50~ 9.3) \[[11](http://www.ncbi.nlm.nih.gov/pubmed/10633034?dopt=AbstractPlus)\], [clobetasol propionate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7062) (p*K* ~i~ 9.2) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [desoximetasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7067) (p*K* ~i~ 8.9) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [fluorometholone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7079) (p*K* ~i~ 8.8) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [flunisolide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7076) (p*K* ~i~ 8.6) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [diflorasone diacetate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7068) (p*K* ~i~ 8.5) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [fluocinolone acetonide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7077) (pIC~50~ 8.5) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [beclometasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7059) (p*K* ~i~ 8.4) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [methylprednisolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7088) (p*K* ~i~ 8.3) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [fluocinonide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7078) (pIC~50~ 8.3) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [betamethasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7061) (pIC~50~ 8.1) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [budesonide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7434) (pEC~50~ 7.9) \[[102](http://www.ncbi.nlm.nih.gov/pubmed/21880489?dopt=AbstractPlus)\], [triamcinolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2870) (pIC~50~ 7.7) \[[87](http://www.ncbi.nlm.nih.gov/pubmed/10747884?dopt=AbstractPlus)\], [ZK216348](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8643) (pIC~50~ 7.7) \[[132](http://www.ncbi.nlm.nih.gov/pubmed/14694204?dopt=AbstractPlus)\], [ciclesonide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7469) (p*K* ~i~ 7.4) \[[6](http://www.ncbi.nlm.nih.gov/pubmed/15878996?dopt=AbstractPlus)\], [prednisone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7096) (p*K* ~i~ 6.3) \[\[[3](#bph13352-bib-0003){ref-type="ref"}\]\], [RU26988](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3446) -- Unknown, [RU28362](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3445), [difluprednate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7474) \[[145](http://www.ncbi.nlm.nih.gov/pubmed/21182429?dopt=AbstractPlus)\], [fluticasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6699)--[medroxyprogesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2879) (Affinity at human PR‐A) (p*K* ~i~ 9.5) \[[170](http://www.ncbi.nlm.nih.gov/pubmed/9464360?dopt=AbstractPlus)\], [ORG2058](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3453), [levonorgestrel](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2881) \[[10](http://www.ncbi.nlm.nih.gov/pubmed/6645495?dopt=AbstractPlus), [130](http://www.ncbi.nlm.nih.gov/pubmed/14670641?dopt=AbstractPlus)\]Antagonists[cyproterone acetate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2865) (p*K* ~i~ 7.8) \[[55](http://www.ncbi.nlm.nih.gov/pubmed/9484511?dopt=AbstractPlus)\][mifepristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2805) (p*K* ~d~ 9.4) \[[57](http://www.ncbi.nlm.nih.gov/pubmed/3560943?dopt=AbstractPlus), [127](http://www.ncbi.nlm.nih.gov/pubmed/8282004?dopt=AbstractPlus)\][nimodipine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2523) (inhibition of aldosterone‐induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain) (pIC~50~ 6.8) \[[34](http://www.ncbi.nlm.nih.gov/pubmed/18250364?dopt=AbstractPlus)\]--Selective antagonists[bicalutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2863) (p*K* ~i~ 7.7) \[[71](http://www.ncbi.nlm.nih.gov/pubmed/16420057?dopt=AbstractPlus)\], [PF0998425](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6698) (pIC~50~ 7.1--7.5) \[[86](http://www.ncbi.nlm.nih.gov/pubmed/18921992?dopt=AbstractPlus)\], [enzalutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6812) (pIC~50~ 7.4) \[[148](http://www.ncbi.nlm.nih.gov/pubmed/19359544?dopt=AbstractPlus)\], [nilutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2864) (pIC~50~ 7.1--7.1) \[[136](http://www.ncbi.nlm.nih.gov/pubmed/9111629?dopt=AbstractPlus)\], [hydroxyflutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2862) (pEC~50~ 6.6) \[[152](http://www.ncbi.nlm.nih.gov/pubmed/10076535?dopt=AbstractPlus)\], [galeterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638) (pIC~50~ 6.4) \[[56](http://www.ncbi.nlm.nih.gov/pubmed/15828836?dopt=AbstractPlus)\], [flutamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6943) (Displacement of ^3^\[H\] testosterone from wild‐type androgen receptors) (p*K* ~i~ 5.4) \[[151](http://www.ncbi.nlm.nih.gov/pubmed/18571420?dopt=AbstractPlus)\][onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882) (pIC~50~ 7.6) \[[169](http://www.ncbi.nlm.nih.gov/pubmed/12781198?dopt=AbstractPlus)\], [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)[finerenone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8678) (pIC~50~ 7.7) \[[21](http://www.ncbi.nlm.nih.gov/pubmed/22791416?dopt=AbstractPlus)\], [eplerenone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2876) (p*K* ~i~ 6.9) \[[5](http://www.ncbi.nlm.nih.gov/pubmed/18038968?dopt=AbstractPlus)\], [onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882) (pIC~50~ 6.3) \[[169](http://www.ncbi.nlm.nih.gov/pubmed/12781198?dopt=AbstractPlus)\], [RU28318](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3451), [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)[ulipristal acetate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7460) (pIC~50~ 9.7) \[[124](http://www.ncbi.nlm.nih.gov/pubmed/18243712?dopt=AbstractPlus)\], [mifepristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2805) (Mixed) (p*K* ~i~ 9) \[[171](http://www.ncbi.nlm.nih.gov/pubmed/12781197?dopt=AbstractPlus)\], [onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882) (p*K* ~i~ 7.7) \[[54](http://www.ncbi.nlm.nih.gov/pubmed/8627601?dopt=AbstractPlus)\], [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)Labelled ligands[\[^3^H\]dihydrotestosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3455) (Selective Agonist), [\[^3^H\]methyltrienolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3457) (Selective Agonist), [\[^3^H\]mibolerone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3456) (Agonist)[\[^3^H\]dexamethasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3447) (Agonist)[\[^3^H\]aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3452) (Selective Agonist) (p*K* ~d~ 9.5--9.4) \[[44](http://www.ncbi.nlm.nih.gov/pubmed/16188378?dopt=AbstractPlus), [140](http://www.ncbi.nlm.nih.gov/pubmed/6320679?dopt=AbstractPlus)\] -- Rat[\[^3^H\]ORG2058](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3454) (Selective Agonist)

Comments {#bph13352-sec-0067}
--------

[\[^3^H\]dexamethasone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3447) also binds to MR*in vitro*. PR antagonists have been suggested to subdivide into Type I (*e.g.* [onapristone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2882)) and Type II (*e.g*. [ZK112993](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3448)) groups. These groups appear to promote binding of PR to DNA with different efficacies and evoke distinct conformational changes in the receptor, leading to a transcription‐neutral complex \[[43](http://www.ncbi.nlm.nih.gov/pubmed/9528977?dopt=AbstractPlus), [83](http://www.ncbi.nlm.nih.gov/pubmed/9849965?dopt=AbstractPlus)\]. Mutations in AR underlie testicular feminization and androgen insensibility syndromes, spinal and bulbar muscular atrophy (Kennedy\'s disease).
